Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. more
Time Frame | SUPN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.42% | -3.39% | 0.2% |
1-Month Return | 2.75% | -1.92% | 2.72% |
3-Month Return | 14.19% | -10.54% | 7.31% |
6-Month Return | 39.36% | -4.47% | 10.44% |
1-Year Return | 32.72% | 4.06% | 27.53% |
3-Year Return | 26.25% | 0.94% | 30.88% |
5-Year Return | 57.55% | 36.67% | 89.21% |
10-Year Return | 314.42% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 392.75M | 520.40M | 579.77M | 667.24M | 607.52M | [{"date":"2019-12-31","value":58.86,"profit":true},{"date":"2020-12-31","value":77.99,"profit":true},{"date":"2021-12-31","value":86.89,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.05,"profit":true}] |
Cost of Revenue | 16.66M | 52.46M | 75.06M | 87.22M | 83.78M | [{"date":"2019-12-31","value":19.1,"profit":true},{"date":"2020-12-31","value":60.14,"profit":true},{"date":"2021-12-31","value":86.06,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.05,"profit":true}] |
Gross Profit | 376.10M | 467.94M | 504.71M | 580.02M | 523.74M | [{"date":"2019-12-31","value":64.84,"profit":true},{"date":"2020-12-31","value":80.68,"profit":true},{"date":"2021-12-31","value":87.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":90.3,"profit":true}] |
Gross Margin | 95.76% | 89.92% | 87.05% | 86.93% | 86.21% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.9,"profit":true},{"date":"2021-12-31","value":90.91,"profit":true},{"date":"2022-12-31","value":90.78,"profit":true},{"date":"2023-12-31","value":90.03,"profit":true}] |
Operating Expenses | 227.52M | 292.34M | 425.21M | 534.40M | 529.01M | [{"date":"2019-12-31","value":42.58,"profit":true},{"date":"2020-12-31","value":54.7,"profit":true},{"date":"2021-12-31","value":79.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.99,"profit":true}] |
Operating Income | 148.57M | 173.70M | 86.03M | 67.30M | (5.27M) | [{"date":"2019-12-31","value":85.53,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":49.53,"profit":true},{"date":"2022-12-31","value":38.75,"profit":true},{"date":"2023-12-31","value":-3.03,"profit":false}] |
Total Non-Operating Income/Expense | (2.17M) | (10.10M) | (25.71M) | 29.24M | 14.90M | [{"date":"2019-12-31","value":-7.42,"profit":false},{"date":"2020-12-31","value":-34.54,"profit":false},{"date":"2021-12-31","value":-87.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":50.95,"profit":true}] |
Pre-Tax Income | 147.49M | 168.65M | 73.17M | 60.74M | 2.77M | [{"date":"2019-12-31","value":87.45,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":43.39,"profit":true},{"date":"2022-12-31","value":36.02,"profit":true},{"date":"2023-12-31","value":1.64,"profit":true}] |
Income Taxes | 34.43M | 41.70M | 19.75M | 32.00K | 1.45M | [{"date":"2019-12-31","value":82.57,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":47.37,"profit":true},{"date":"2022-12-31","value":0.08,"profit":true},{"date":"2023-12-31","value":3.48,"profit":true}] |
Income After Taxes | 113.06M | 126.95M | 53.42M | 60.71M | 1.32M | [{"date":"2019-12-31","value":89.06,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":47.82,"profit":true},{"date":"2023-12-31","value":1.04,"profit":true}] |
Income From Continuous Operations | 113.06M | 126.95M | 53.42M | 60.71M | 25.62M | [{"date":"2019-12-31","value":89.06,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":47.82,"profit":true},{"date":"2023-12-31","value":20.18,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 113.06M | 126.95M | 53.42M | 60.71M | 1.32M | [{"date":"2019-12-31","value":89.06,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":47.82,"profit":true},{"date":"2023-12-31","value":1.04,"profit":true}] |
EPS (Diluted) | 2.11 | 2.36 | 0.98 | 1.03 | 1.40 | [{"date":"2019-12-31","value":89.41,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":41.53,"profit":true},{"date":"2022-12-31","value":43.64,"profit":true},{"date":"2023-12-31","value":59.32,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
SUPN | |
---|---|
Cash Ratio | 1.38 |
Current Ratio | 2.20 |
Quick Ratio | 1.98 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SUPN | |
---|---|
ROA (LTM) | 2.89% |
ROE (LTM) | 6.22% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SUPN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.25 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.75 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SUPN | |
---|---|
Trailing PE | 33.85 |
Forward PE | 20.16 |
P/S (TTM) | 3.07 |
P/B | 2.00 |
Price/FCF | 38 |
EV/R | 2.53 |
EV/Ebitda | 10.60 |
PEG | 1.47 |
Supernus Pharmaceuticals Inc (SUPN) share price today is $35.517
Yes, Indians can buy shares of Supernus Pharmaceuticals Inc (SUPN) on Vested. To buy Supernus Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SUPN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Supernus Pharmaceuticals Inc (SUPN) via the Vested app. You can start investing in Supernus Pharmaceuticals Inc (SUPN) with a minimum investment of $1.
You can invest in shares of Supernus Pharmaceuticals Inc (SUPN) via Vested in three simple steps:
The 52-week high price of Supernus Pharmaceuticals Inc (SUPN) is $39.37. The 52-week low price of Supernus Pharmaceuticals Inc (SUPN) is $25.53.
The price-to-earnings (P/E) ratio of Supernus Pharmaceuticals Inc (SUPN) is 33.8505
The price-to-book (P/B) ratio of Supernus Pharmaceuticals Inc (SUPN) is 2.00
The dividend yield of Supernus Pharmaceuticals Inc (SUPN) is 0.00%
The market capitalization of Supernus Pharmaceuticals Inc (SUPN) is $2.00B
The stock symbol (or ticker) of Supernus Pharmaceuticals Inc is SUPN